Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.
about
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerOmentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progressionRadium-223 dichloride in clinical practice: a review.Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasisAndrogen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.Chemotherapeutic inhibitors in the treatment of prostate cancer.Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer.Advances in systemic therapies for metastatic castration-resistant prostate cancer.Development of enzalutamide for metastatic castration-resistant prostate cancer.XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).Therapeutic management of bone metastasis in prostate cancer: an update.Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.Current approaches to incorporation of radium-223 in clinical practice.Integrated approach to pain management for a patient with multiple bone metastases of uterine cervical cancer.Patient preferences for treatments to delay bone metastases.Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.
P2860
Q26752785-B787BE16-E7C9-46EF-8667-6CC7B71DADBFQ28076686-8AB77A70-C748-4061-9E16-153C8F77F2AFQ30251496-78234CD6-7277-40F4-8EF2-99105392C8C9Q33924147-CE00EB42-6D46-46D5-9966-FD2826DA3EE0Q34448130-85B9A0C2-5D92-41F8-8C54-5A7AE29DC272Q35774987-63282F28-79E4-4C51-AE5B-B594282B4CDBQ37613978-338CBBAD-DE33-42D1-AA03-7600CF5F8846Q38155239-01278F11-07C9-4E86-ABC7-E1D7B082F700Q38244522-8BA7E499-6780-4A4E-A894-1ECA108957C0Q38252425-441B8104-DD47-40A9-87DB-44146A4AC1DFQ38282461-6D0CE36A-35E3-4CF8-8C41-30A6108F699FQ38589130-30E99525-5934-49FD-8C22-F0BCD74F06F0Q38950408-5E679FBD-AA2C-4205-A335-D05A1F83E4FAQ38964037-227FF711-2F33-4BAE-9139-C979681A623BQ41382610-56A9410C-7F43-4051-8765-6E19C6BEF4DBQ47212646-969467B5-03E4-436D-8E3C-A7B0A758A7EDQ52349317-A7C77615-777A-439A-A220-2B3B099EB70CQ53264477-A766BCF1-2CA6-44C4-A233-66250F3E616BQ55331819-DE3DCE89-015E-4003-8F42-4F605095CD73
P2860
Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bone-targeted therapies in met ...... te cancer: evolving paradigms.
@en
Bone-targeted therapies in met ...... te cancer: evolving paradigms.
@nl
type
label
Bone-targeted therapies in met ...... te cancer: evolving paradigms.
@en
Bone-targeted therapies in met ...... te cancer: evolving paradigms.
@nl
prefLabel
Bone-targeted therapies in met ...... te cancer: evolving paradigms.
@en
Bone-targeted therapies in met ...... te cancer: evolving paradigms.
@nl
P2093
P2860
P356
P1433
P1476
Bone-targeted therapies in met ...... ate cancer: evolving paradigms
@en
P2093
Ashley Freeman
Joelle El-Amm
Nihar Patel
P2860
P304
P356
10.1155/2013/210686
P577
2013-08-28T00:00:00Z